News

miRagen Therapeutics announces orphan drug designation

Thursday, February 17, 2011

miRagen Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's compound MGN-4893 for the treatment of polycythemia vera, a myeloproliferative disease characterized by an overabundance of blood cells and platelets in the body. MGN-4893 targets microRNA-451, which has been demonstrated in recent studies to play a crucial role in the regulation of blood cell development. miRagen is currently conducting pre-clinical studies and expects to initiate human clinical trials in 2012. 

CBSA President & CEO on 9News with Gary Shapiro

Thursday, February 17, 2011

CBSA President & CEO interviewed on 9News with Gary Shapiro about job opportunities in Colorado's Bioscience Industry and shared details about today's Biotech & Pharma Symposium 

Covidien announces 510(k) clearance

Wednesday, February 16, 2011

Covidien (Boulder) announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LigaSure™ Curved, Small Jaw, Open Sealer/Divider surgical instrument. The device is indicated for use in general surgery and will be available in the United States this quarter. 

AmideBio’s Misha Plam Receives SBA Award

Tuesday, February 15, 2011

Boulder, CO—AmideBio, LLC today announced that its co-founder and CEO, Dr. Misha Plam, has received the Tibbetts Award from the U.S. Small Business Administration (SBA) for his distinguished record of entrepreneurship and innovation and for his contributions in promoting the SBA’s Small Business Innovation Research (SBIR) program in the U.S. and abroad, especially in Russia and China. 

Holli Baumunk on Business for Breakfast

Tuesday, February 15, 2011

CBSA's President & CEO Holli Baumunk interviewed on the Radio Colorado Network's Business for Breakfast Show 

Mesa Laboratories reports increase in revenue

Monday, February 14, 2011

Mesa Laboratories, Inc. (Lakewood) reported a 44 percent increase in revenue and a 19 percent increase in non-GAAP(1) net income for the fiscal third quarter ended December 31, 2010.  During the quarter. Mesa Laboratories completed the acquisition of Apex Laboratories.   

CBSA Launches 2011 Symposium Series with "Biotech & Pharma" Session

Monday, February 14, 2011

Denver, CO – February 14, 2011 – The Colorado BioScience Association (CBSA) is launching its 2011 Symposium Series Thursday, February 17, with the session, "Biotech & Pharma," 1‐7 p.m., at the Grand Hyatt Denver, 1750 Welton Street. The announcement is made by Holli Baumunk, CBSA President & CEO, who says the CBSA's new Symposium Series is being held quarterly this year, with each program focusing intently for a half day on matters of key interest to the state's Bioscience Industry. Upcoming symposiums are planned for June 9 covering Science Investment Opportunities & Options; August 11, Regulatory & Reimbursement Issues; and November 10, Medical Device & Diagnostic Development. 

Medical device makers oppose manufacturing tax

Friday, February 11, 2011

Denver Business Journal - by Greg Avery
Colorado’s medical device makers are rallying behind federal legislation to repeal a tax on their sales that’s predicted to raise $20 billion for overhauling the nation’s health care. 

Democrats: Prove that incentives create jobs

Friday, February 11, 2011

Denver Business Journal - by Ed Sealover
Last year, Statehouse Democrats pushed through cuts in the number of tax credits given to businesses, raising $140 million in new revenue for Colorado. 

miRagen Therapeutics at Keystone Symposia

Friday, February 11, 2011

miRagen Therapeutics, Inc announced that its Co-Founder/Chief Scientific Advisor, Eric N. Olson, Ph.D., and scientific Co-Founder/Director of Biology, Eva van Rooij, Ph.D., are serving as Scientific Organizers as well as presenters at the first Keystone Symposia on Molecular and Cellular Biology conference focused on MicroRNAs and Human Disease. The conference will take place February 11-16, 2011, in Banff, Alberta, Canada.